Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Faeth Therapeutics, Inc.

NASDAQ: FTH · Life Sciences · 6 alerts · CIK 1829802

Share price
$9.28Close, Nov 16
Market cap
$240M
Shares outstanding
25.84MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Faeth Therapeutics, Inc. filings on SEC EDGAR ↗

8:46 AM ET 8-K
Clinical Trial Data

Faeth Therapeutics Clinical Trial Data

Faeth Therapeutics announced topline clinical data from its Phase 2 PIK-201 trial evaluating its product candidate PIKTOR in patients with advanced endometrial cancer. The trial evaluated PIKTOR (a combination of serabelisib and sapanisertib) in combination with paclitaxel. The company released a corporate presentation detailing these preliminary efficacy and safety results to investors.

7:20 AM ET 8-K
Clinical Trial Data

Faeth Therapeutics Clinical Trial Data

Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.

Counterparty
The GOG Foundation, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.